Cargando…

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

OBJECTIVE: Compare outcomes in patients with stage III non–small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone. METHODS: The records of patients with stage III NSCLC treated with definitive chemoradiation ± adjuv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saad, Akram, Goldstein, Jeffrey, Appel, Sarit, Daher, Sameh, Urban, Damien, Onn, Amir, Gantz‐Sorotsky, Hadas, Lobachov, Anastasiya, Gottfried, Teodor, Spieler, Benjamin, Bar, Jair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200887/ https://www.ncbi.nlm.nih.gov/pubmed/35538909 http://dx.doi.org/10.1111/1759-7714.14452

Ejemplares similares

Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery
por: Appel, Sarit, et al.
Publicado: (2023)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
por: Onn, Amir, et al.
Publicado: (2021)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Cost‐effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus
por: Salcedo, Jonathan, et al.
Publicado: (2019)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Sarcoid-Like Granulomatosis of the Lung Related to Durvalumab After Chemoradiation for Pulmonary Squamous Cell Carcinoma
por: Minami, Seigo, et al.
Publicado: (2023)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
por: Magri, Valentina, et al.
Publicado: (2019)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus
por: Tudu, Rajanigandha
Publicado: (2020)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016)

Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
por: Bar, Jair, et al.
Publicado: (2021)

Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
por: Zhao, Lina, et al.
Publicado: (2017)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Concurrent Chemoradiation for Vaginal Cancer
por: Miyamoto, David T., et al.
Publicado: (2013)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial
por: Nunes de Arruda, Fernanda, et al.
Publicado: (2020)

Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients
por: Mowry, Sarah E., et al.
Publicado: (2009)

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer
por: Kim, Jin K, et al.
Publicado: (2022)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
por: Matsuura, Shun, et al.
Publicado: (2023)

Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
por: Grassi, E., et al.
Publicado: (2023)

Chemoradiation. An Integrated Approach to Cancer Treatment
por: Duchesne, G.M.
Publicado: (1994)

Lymphopenia during chemoradiation—foe or friend
por: Patil, Vijay M, et al.
Publicado: (2020)

Self-reported sleep quality as prognostic for survival in lung cancer patients
por: Gottfried, Teodor, et al.
Publicado: (2020)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022)

Neoadjuvant Chemoradiation Compared With Neoadjuvant Radiation Alone in the Management of High-Grade Soft Tissue Extremity Sarcomas
por: Hazell, Sarah Z., et al.
Publicado: (2019)

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial
por: Li, Jing, et al.
Publicado: (2022)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7pfkgqvgbocatmammhfu79ab3a